To validate these findings in in vivo PDX models, we injected aRMS-1 (IC-pPDX-104) cells orthotopically and subcutaneously and measured the effect of a 2-week drug treatment on tumor differentiation and growth inhibition (Fig. 7C and table S7). Here, CFH is linked to neoplasm.